AgomAb Therapeutics (NASDAQ:AGMB) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB) in a report issued on Wednesday, MarketBeat reports. The brokerage issued an overweight rating on the stock.

AGMB has been the topic of several other reports. Wall Street Zen lowered AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. B. Riley Financial began coverage on AgomAb Therapeutics in a research report on Thursday, July 23rd. They set a “buy” rating and a $34.00 target price on the stock. Finally, HC Wainwright assumed coverage on shares of AgomAb Therapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $35.00 price target on the stock. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.00.

AgomAb Therapeutics Trading Down 1.3%

AGMB stock opened at $13.25 on Wednesday. AgomAb Therapeutics has a one year low of $8.75 and a one year high of $17.82. The firm’s fifty day moving average price is $12.88.

AgomAb Therapeutics (NASDAQ:AGMB) last posted its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. Research analysts predict that AgomAb Therapeutics will post -1.71 earnings per share for the current year.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.